NEXTCURE INC (NXTC)

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 99 full-time employees. The company went IPO on 2019-05-09. The firm is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, it is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC410, NC762 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein (B7-H4) a protein expressed on multiple tumor types. NC525 (LAIR-1 mAb) is a LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells (LSCs).

Company Info

NEXTCURE INC

9000 Virginia Manor Rd Ste 200

Beltsville MARYLAND 20705

P: 12403994900

CEO: Michael Richman

Employees: 99

Website: https://www.nextcure.com/